# Study of DARE-HRT1 Over 12 Weeks in Healthy PostMenopausal Women

> **NCT05367973** · PHASE1,PHASE2 · COMPLETED · sponsor: **Daré Bioscience, Inc.** · enrollment: 21 (actual)

## Conditions studied

- Vulvovaginal Atrophy
- Vasomotor Symptoms

## Interventions

- **DEVICE:** IVR Dose 1
- **DEVICE:** IVR Dose 2

## Key facts

- **NCT ID:** NCT05367973
- **Lead sponsor:** Daré Bioscience, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-11
- **Primary completion:** 2023-01-09
- **Final completion:** 2023-03-23
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2024-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05367973

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05367973, "Study of DARE-HRT1 Over 12 Weeks in Healthy PostMenopausal Women". Retrieved via AI Analytics 2026-08-02 from https://api.ai-analytics.org/clinical/NCT05367973. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*